Innovation from non-industrial sources

被引：1

作者：

Mulligan, L ^{[1
]}

Steele, P ^{[1
]}

机构：

[1] Current Patents Ltd, London W1P 6LB, England

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2000年 / 10卷 / 01期

基金：

美国国家科学基金会; 英国医学研究理事会;

关键词：

analytical techniques; infection; innovation; intellectual property rights; neoplasm; non-industrial institutions; University of California; USNIH; US-based entities;

D O I：

10.1517/13543776.10.1.17

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Eight thousand therapeutic patent documents originating from non-industrial institutions, published during the past five years, were analysed. Innovation in this sector was found to be dominated by US-based entities, principally the National Institutes of Health (NM) and the University of California; the only non-US applicants featuring in the top-20 were INSERM of France and the UK's Medical Research Council (MRC). Patenting levels are increasing steadily, but direct government involvement in obtaining intellectual property rights may now be declining. Neoplasm and infection followed by neurological and cardiovascular disorders, as in the industrial sector, are the principal targets for this sector, although with some differences of emphasis. The University of California's patenting is analysed in detail, in order to exemplify the analytical techniques which have been applied to these data.

引用

页码：17 / 24

页数：8